Conclusions and Relevance This systematic review and meta- analysis did not show a significant beneficial or detrimental association of HT with muscle mass .
Importance Hormone therapy ( HT ) has been suggested for protection against age-related muscle weakness in women .
However , the potential for HT-associated health risks necessitates a better underst and ing of the direction and magnitude of the association between HT and health outcomes , such as lean body mass ( LBM ) .
Objective To determine whether HT was associated with reduced LBM loss compared with not receiving HT  among postmenopausal women aged 50 years and older .
Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study.
BACKGROUND AND AIMS sarcopenia has been indicated as a reliable marker of frailty and poor prognosis among the oldest individuals . We evaluated the impact of sarcopenia on the risk of all-cause death in a population of frail older persons living in community . METHODS we analysed data from the Aging and Longevity Study , a prospect i ve cohort study that collected data on all subjects aged 80 years and older residing in the Sirente geographic area ( n = 364 ) . The present analysis was conducted among those subjects who were between 80 and 85 years of age at the time of the baseline assessment ( n = 197 ) . The main outcome measure was all-cause mortality over 7-year follow-up . According to the European Working Group on Sarcopenia in Older People ( EWGSOP ) criteria , the diagnosis of sarcopenia required the documentation of low muscle mass and the documentation of either low muscle strength or low physical performance . Cox proportional regression models were used to estimate crude and adjusted hazard ratios and 95 % confidence intervals of death by the presence of sarcopenia . RESULTS using the EWGSOP-suggested criteria , 43 subjects with sarcopenia ( 21.8 % ) were identified . During the 7-year follow-up , 29 ( 67.4 % ) participants died among subjects with sarcopenia compared with 63 subjects ( 41.2 % ) without sarcopenia ( P < 0.001 ) . After adjusting for potential confounders including age , gender , education , activities of daily living ( ADL ) impairment , body mass index , hypertension , congestive heart failure , chronic obstructive pulmonary disease , number of diseases , TNF-α , participants with sarcopenia had a higher risk of death for all causes compared with non-sarcopenic subjects ( HR : 2.32 , 95 % CI : 1.01 - 5.43 ) . CONCLUSIONS our results obtained from a representative sample of very old and frail subjects show that sarcopenia is associated with mortality , independently of age and other clinical and functional variables
Conclusions and Relevance This systematic review and meta- analysis did not show a significant beneficial or detrimental association of HT with muscle mass .
Importance Hormone therapy ( HT ) has been suggested for protection against age-related muscle weakness in women .
However , the potential for HT-associated health risks necessitates a better underst and ing of the direction and magnitude of the association between HT and health outcomes , such as lean body mass ( LBM ) .
Objective To determine whether HT was associated with reduced LBM loss compared with not receiving HT  among postmenopausal women aged 50 years and older .